Your browser is no longer supported. Please, upgrade your browser.
AZN [NASD]
AstraZeneca PLC
Index- P/E55.99 EPS (ttm)0.95 Insider Own0.50% Shs Outstand2.62B Perf Week3.82%
Market Cap140.35B Forward P/E17.95 EPS next Y2.97 Insider Trans0.00% Shs Float2.60B Perf Month7.19%
Income2.50B PEG2.89 EPS next Q0.68 Inst Own16.80% Short Float1.29% Perf Quarter3.26%
Sales25.87B P/S5.42 EPS this Y-39.70% Inst Trans0.04% Short Ratio3.27 Perf Half Y-3.48%
Book/sh4.65 P/B11.45 EPS next Y19.73% ROA4.10% Target Price62.48 Perf Year6.08%
Cash/sh3.20 P/C16.62 EPS next 5Y19.40% ROE20.70% 52W Range36.15 - 64.94 Perf YTD6.52%
Dividend1.40 P/FCF- EPS past 5Y1.00% ROI8.30% 52W High-18.00% Beta0.56
Dividend %2.63% Quick Ratio0.80 Sales past 5Y-1.70% Gross Margin80.10% 52W Low47.30% ATR0.96
Employees70600 Current Ratio1.00 Sales Q/Q2.70% Oper. Margin16.40% RSI (14)62.78 Volatility1.20% 1.44%
OptionableYes Debt/Eq1.83 EPS Q/Q116.60% Profit Margin9.70% Rel Volume1.30 Prev Close52.55
ShortableYes LT Debt/Eq1.54 EarningsFeb 11 BMO Payout147.40% Avg Volume10.25M Price53.25
Recom1.60 SMA205.41% SMA501.59% SMA200-0.38% Volume13,367,273 Change1.33%
Jan-15-21Initiated Deutsche Bank Buy
Dec-07-20Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-30-20Upgrade UBS Sell → Neutral
Nov-11-20Upgrade HSBC Securities Reduce → Hold
Sep-29-20Initiated Berenberg Buy
Nov-22-19Initiated SVB Leerink Outperform
Oct-25-19Upgrade Liberum Hold → Buy
Apr-02-19Downgrade UBS Neutral → Sell
Feb-05-19Initiated Exane BNP Paribas Outperform
Jan-25-19Upgrade Shore Capital Hold → Buy
Dec-11-18Resumed Jefferies Hold
Oct-09-18Initiated Guggenheim Buy
Aug-16-18Downgrade Jefferies Buy → Hold
Mar-19-18Upgrade Jefferies Hold → Buy
Feb-06-18Reiterated Leerink Partners Mkt Perform $36 → $38
Feb-05-18Reiterated Bernstein Outperform $40 → $42
Jan-18-18Reiterated Leerink Partners Mkt Perform $33 → $36
Dec-29-17Upgrade JP Morgan Neutral → Overweight
Oct-16-17Upgrade Credit Suisse Neutral → Outperform
Sep-25-17Upgrade Exane BNP Paribas Neutral → Outperform
Jan-23-21 08:22AM  
04:40AM  
02:56AM  
Jan-22-21 04:48PM  
03:22PM  
11:39AM  
09:40AM  
08:27AM  
07:00AM  
Jan-21-21 09:59AM  
09:18AM  
07:14AM  
06:35AM  
05:37AM  
02:39AM  
Jan-20-21 05:50PM  
12:08PM  
08:33AM  
02:56AM  
Jan-19-21 01:57PM  
01:25PM  
11:50AM  
11:44AM  
08:37AM  
06:44AM  
Jan-18-21 07:00AM  
06:44AM  
06:07AM  
05:51AM  
Jan-16-21 08:55PM  
03:20AM  
Jan-15-21 06:30PM  
12:56PM  
Jan-14-21 04:53PM  
04:17PM  
02:26PM  
Jan-13-21 05:50PM  
01:02PM  
11:07AM  
09:57AM  
09:00AM  
06:01AM  
05:32AM  
05:22AM  
Jan-12-21 08:06PM  
05:45PM  
11:42AM  
11:03AM  
09:18AM  
09:00AM  
08:15AM  
08:15AM  
07:15AM  
Jan-11-21 05:45PM  
04:01PM  
03:42PM  
03:06PM  
10:54AM  
10:15AM  
08:45AM  
06:41AM  
Jan-10-21 07:01PM  
12:14PM  
Jan-09-21 06:04AM  
Jan-08-21 11:22PM  
03:26PM  
03:14PM  
01:33PM  
12:59PM  
09:00AM  
08:54AM  
Jan-07-21 03:12PM  
10:20AM  
09:52AM  
09:29AM  
08:39AM  
06:30AM  
Jan-06-21 07:01PM  
05:30PM  
04:47PM  
11:42AM  
10:26AM  
10:06AM  
09:32AM  
07:00AM  
05:51AM  
04:07AM  
02:30AM  
12:00AM  
Jan-05-21 07:50PM  
05:45PM  
04:05PM  
02:19PM  
10:12AM  
08:57AM  
07:00AM  
07:00AM  
Jan-04-21 07:30PM  
04:19PM  
02:44PM  
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR/Komboglyze, Onglyza, Qtern, Symlin, Xigduo/Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Tudorza/Eklira, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalen and Synagis for infection diseases; Movantik/Moventig, Seroquel IR/Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Arcus Biosciences, Inc. to evaluate domvanalimab (AB154), an investigational anti-TIGIT antibody in combination with Imfinzi (durvalumab); Fusion Pharmaceuticals Inc. to develop and commercialize next-generation alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer; and Recombinetics Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.